

# Bertha K Madras

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/464805/publications.pdf>

Version: 2024-02-01

110  
papers

6,997  
citations

66234

42  
h-index

62479

80  
g-index

110  
all docs

110  
docs citations

110  
times ranked

6089  
citing authors

#	ARTICLE	IF	CITATIONS
1	In memoriam professor Philip Seeman (February 8, 1934-January 9, 2021). <i>Neuropsychopharmacology</i> , 2021, 46, 1229-1230.	2.8	1
2	Effects of daily $\Delta^9$ -Tetrahydrocannabinol (THC) alone or combined with cannabidiol (CBD) on cognition-based behavior and activity in adolescent nonhuman primates. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108629.	1.6	17
3	$\Delta^9$ -Tetrahydrocannabinol Increases Dopamine D1-D2 Receptor Heteromer and Elicits Phenotypic Reprogramming in Adult Primate Striatal Neurons. <i>IScience</i> , 2020, 23, 100794.	1.9	22
4	Dopamine D1-D2 receptor heteromer expression in key brain regions of rat and higher species: Upregulation in rat striatum after cocaine administration. <i>Neurobiology of Disease</i> , 2020, 143, 105017.	2.1	22
5	THC and CBD blood and brain concentrations following daily administration to adolescent primates. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108129.	1.6	14
6	Sex difference in dopamine D1-D2 receptor complex expression and signaling affects depression- and anxiety-like behaviors. <i>Biology of Sex Differences</i> , 2020, 11, 8.	1.8	49
7	Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers Within the Treatment System. <i>NAM Perspectives</i> , 2020, 2020, .	1.3	90
8	Cannabinoid and Marijuana Neurobiology. , 2020, , 25-47.		0
9	Psychiatry and the Opioid Overdose Crisis. <i>Focus (American Psychiatric Publishing)</i> , 2019, 17, 128-133.	0.4	7
10	Tinkering with THC-to-CBD ratios in Marijuana. <i>Neuropsychopharmacology</i> , 2019, 44, 215-216.	2.8	18
11	Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse. <i>JAMA Network Open</i> , 2019, 2, e1916015.	2.8	36
12	The President's Commission on Combating Drug Addiction and the Opioid Crisis: Origins and Recommendations. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 943-945.	2.3	59
13	Pharmacological Research as a Key Component in Mitigating the Opioid Overdose Crisis. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 995-998.	4.0	47
14	Drug use among youth: National survey data support a common liability of all drug use. <i>Preventive Medicine</i> , 2018, 113, 68-73.	1.6	38
15	Are THC Levels in Oral Fluids and Blood Plasma Comparable after Oral Ingestion of Edibles Containing Cannabis or THC?. <i>Clinical Chemistry</i> , 2017, 63, 629-631.	1.5	8
16	The Surge of Opioid Use, Addiction, and Overdoses. <i>JAMA Psychiatry</i> , 2017, 74, 441.	6.0	89
17	Ineffective Policies to Address the Opioid Epidemic—Reply. <i>JAMA Psychiatry</i> , 2017, 74, 974.	6.0	0
18	The Growing Problem of New Psychoactive Substances (NPS). <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 1-18.	0.8	51

#	ARTICLE	IF	CITATIONS
19	Cannabis and Medicinal Properties. South Dakota Medicine: the Journal of the South Dakota State Medical Association, 2016, No, 34-45.	0.2	0
20	Vesicular Monoamine Transporter 2 Loss in Human Cocaine Abusers Confirmed in Nonhuman Primate Brain. Biological Psychiatry, 2015, 77, 421-422.	0.7	0
21	Dopamine challenge reveals neuroadaptive changes in marijuana abusers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11915-11916.	3.3	3
22	Drug Use and Its Consequences. , 2014, , 1-35.		1
23	History of the Discovery of the Antipsychotic Dopamine D2 Receptor: A Basis for the Dopamine Hypothesis of Schizophrenia. Journal of the History of the Neurosciences, 2013, 22, 62-78.	0.1	85
24	Functional Genomics of Attention-Deficit/Hyperactivity Disorder (ADHD) Risk Alleles on Dopamine Transporter Binding in ADHD and Healthy Control Subjects. Biological Psychiatry, 2013, 74, 84-89.	0.7	44
25	Prescription opioid abuse: challenges and opportunities for payers. American Journal of Managed Care, 2013, 19, 295-302.	0.8	39
26	Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters. Bioorganic and Medicinal Chemistry, 2012, 20, 2762-2772.	1.4	3
27	Candidate Performance Measures for Screening for, Assessing, and Treating Unhealthy Substance Use in Hospitals. Annals of Internal Medicine, 2011, 154, 72.	2.0	4
28	Growth-associated protein-43 and ephrin B3 induction in the brain of adult SIV-infected rhesus macaques. Journal of NeuroVirology, 2011, 17, 455-468.	1.0	2
29	The synthesis and biological evaluation of 2-(3-methyl or Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 347 Td (3-phenylisoxazol-5-yl) 2011, 21, 48-51.	1.0	5
30	Office of National Drug Control Policy. Annals of the New York Academy of Sciences, 2010, 1187, 370-402.	1.8	119
31	A Positron Emission Tomography Study Examining The Dopaminergic Activity of Armodafinil in Adults Using [11C]Altropane and [11C]Raclopride. Biological Psychiatry, 2010, 68, 964-970.	0.7	21
32	Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later. Drug and Alcohol Dependence, 2009, 99, 280-295.	1.6	579
33	MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. Journal of Psychopharmacology, 2008, 22, 187-202.	2.0	24
34	Rhesus Monkey Trace Amine-Associated Receptor 1 Signaling: Enhancement by Monoamine Transporters and Attenuation by the D2 Autoreceptor in Vitro. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 116-127.	1.3	103
35	Further Evidence of Dopamine Transporter Dysregulation in ADHD: A Controlled PET Imaging Study Using Altropane. Biological Psychiatry, 2007, 62, 1059-1061.	0.7	139
36	Synthesis of 8-thiabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters. Bioorganic and Medicinal Chemistry, 2007, 15, 1067-1082.	1.4	7

#	ARTICLE	IF	CITATIONS
37	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) Analogues: A Promising Class of Monoamine Uptake Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1420-1432.	2.9	349
38	Synthesis of 3-(4-heteroaryl-phenyl)-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters. <i>Tetrahedron Letters</i> , 2006, 47, 599-603.	0.7	10
39	MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. <i>Psychopharmacology</i> , 2006, 189, 489-503.	1.5	145
40	Ephrin/Eph receptor expression in brain of adult nonhuman primates: Implications for neuroadaptation. <i>Brain Research</i> , 2006, 1067, 67-77.	1.1	28
41	PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate. <i>American Journal of Psychiatry</i> , 2006, 163, 387-395.	4.0	188
42	Cerebellar Vermis Involvement in Cocaine-Related Behaviors. <i>Neuropsychopharmacology</i> , 2006, 31, 1318-1326.	2.8	90
43	Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 570-585.	1.3	24
44	Modafinil Occupies Dopamine and Norepinephrine Transporters in Vivo and Modulates the Transporters and Trace Amine Activity in Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 561-569.	1.3	304
45	Receptor Regulation of Gene Expression of Axon Guidance Molecules: Implications for Adaptation. <i>Molecular Pharmacology</i> , 2006, 70, 71-77.	1.0	39
46	Dopamine and norepinephrine transporter-dependent c-Fos production in vitro: relevance to neuroadaptation. <i>Journal of Neuroscience Methods</i> , 2005, 143, 69-78.	1.3	5
47	Primate Trace Amine Receptor 1 Modulation by the Dopamine Transporter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 983-994.	1.3	106
48	Variants of the primate vesicular monoamine transporter-2. <i>Molecular Brain Research</i> , 2005, 139, 251-257.	2.5	7
49	The Dopamine Transporter and Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2005, 57, 1397-1409.	0.7	329
50	The Neurobiology of Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2005, 57, 1374-1376.	0.7	7
51	In Vivo Neuroreceptor Imaging in Attention-Deficit/Hyperactivity Disorder: A Focus on The Dopamine Transporter. <i>Biological Psychiatry</i> , 2005, 57, 1293-1300.	0.7	166
52	Repetitive Behaviors in Monkeys Are Linked to Specific Striatal Activation Patterns. <i>Journal of Neuroscience</i> , 2004, 24, 7557-7565.	1.7	128
53	Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 6007-6010.	1.0	9
54	Synthesis and biological activity of 2-Carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 4133-4137.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors. <i>European Journal of Pharmacology</i> , 2003, 479, 41-51.	1.7	13
56	A Second-Generation <sup>99m</sup> Tc Single Photon Emission Computed Tomography Agent That Provides in Vivo Images of the Dopamine Transporter in Primate Brain. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3483-3496.	2.9	11
57	Synthesis and Evaluation of Dopamine and Serotonin Transporter Inhibition by Oxacyclic and Carbacyclic Analogues of Methylphenidate. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1538-1545.	2.9	35
58	Melatonin promotes sleep in three species of diurnal nonhuman primates. <i>Physiology and Behavior</i> , 2002, 75, 523-529.	1.0	123
59	Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. <i>Behavioural Brain Research</i> , 2002, 130, 79-83.	1.2	140
60	The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). <i>Behavioural Brain Research</i> , 2002, 130, 57-63.	1.2	99
61	Design and synthesis of an irreversible dopamine-sparing cocaine antagonist. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 3583-3591.	1.4	22
62	Dopamine transporter-dependent induction of C-Fos in HEK cells. <i>Synapse</i> , 2002, 45, 52-65.	0.6	28
63	Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. <i>Molecular Brain Research</i> , 2001, 87, 124-143.	2.5	74
64	Synthesis of 6- and 7-Hydroxy-8-azabicyclo[3.2.1]octanes and Their Binding Affinity for the Dopamine and Serotonin Transporters. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 2619-2635.	2.9	37
65	Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. <i>Psychopharmacology</i> , 2001, 156, 79-85.	1.5	82
66	Non-amines, drugs without an amine nitrogen, potently block serotonin transport: Novel antidepressant candidates?. <i>Synapse</i> , 2001, 42, 129-140.	0.6	14
67	Synthesis and preliminary characterization of a high-affinity novel radioligand for the dopamine transporter. <i>Synapse</i> , 2001, 39, 175-181.	0.6	7
68	[ <sup>11</sup> C, <sup>127</sup> I] Altropane: A highly selective ligand for PET imaging of dopamine transporter sites. <i>Synapse</i> , 2001, 39, 332-342.	0.6	57
69	[ <sup>3</sup> H]PNU-101958, a D4 dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non-human primate brain. <i>Synapse</i> , 2000, 37, 232-244.	0.6	43
70	3-Aryl-2-carbomethoxybicyclo[3.2.1]oct-2-enes inhibit WIN 35,428 binding potently and selectively at the dopamine transporter. <i>Bioorganic and Medicinal Chemistry</i> , 2000, 8, 581-590.	1.4	21
71	Molecular and regional targets of cocaine in primate brain: liberation from prosaic views. <i>Addiction Biology</i> , 2000, 5, 351-359.	1.4	4
72	Dopamine-transporter density in patients with ADHD. <i>Lancet</i> , The, 2000, 355, 1461-1462.	6.3	8

#	ARTICLE	IF	CITATIONS
73	2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes:Â Potent Non-Nitrogen Inhibitors of Monoamine Transporters. Journal of Medicinal Chemistry, 2000, 43, 2982-2991.	2.9	57
74	Bicyclo[3.2.1]octanes: Synthesis and inhibition of binding at the dopamine and serotonin transporters. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 857-862.	1.0	30
75	Concentration of dopamine transporters: To Bmax or not to Bmax?. Synapse, 1999, 32, 136-140.	0.6	11
76	Non-amine dopamine transporter probe [3H]tropoxene distributes to dopamine-rich regions of monkey brain. Synapse, 1999, 34, 20-27.	0.6	12
77	Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet, The, 1999, 354, 2132-2133.	6.3	590
78	Altoprane, a SPECT or PET imaging probe for dopamine neurons: II. distribution to dopamine-rich regions of primate brain. , 1998, 29, 105-115.		35
79	Altoprane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. , 1998, 29, 116-127.		50
80	Rapid detection of Parkinson's disease by SPECT with altoprane: A selective ligand for dopamine transporters. , 1998, 29, 128-141.		104
81	Altoprane, a SPECT or PET imaging probe for dopamine neurons: I. dopamine transporter binding in primate brain. Synapse, 1998, 29, 93-104.	0.6	36
82	A Technetium-99m SPECT Imaging Agent Which Targets the Dopamine Transporter in Primate Brain. Journal of Medicinal Chemistry, 1997, 40, 1835-1844.	2.9	60
83	Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 462-462.	2.2	2
84	2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes:Â Potent Non-Nitrogen Inhibitors of Monoamine Transporters. Journal of Medicinal Chemistry, 1997, 40, 2661-2673.	2.9	92
85	2-Carbomethoxy-3-(diarylmethoxy)-1,5-dihydro-5H-tropane Analogs:Â Synthesis and Inhibition of Binding at the Dopamine Transporter and Comparison with Piperazines of the GBR Series. Journal of Medicinal Chemistry, 1996, 39, 371-379.	2.9	44
86	Technepine: A high-affinity 99mtechnetium probe to label the dopamine transporter in brain by SPECT imaging. , 1996, 22, 239-246.		64
87	Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT. , 1996, 24, 262-272.		33
88	Nitrogen-based drugs are not essential for blockade of monoamine transporters. , 1996, 24, 340-348.		59
89	Cocaine accumulates in dopamine-rich regions of primate brain after I.V. Administration: Comparison with mazindol distribution. Synapse, 1994, 18, 261-275.	0.6	47
90	11C-WIN 35,428 for detecting dopamine depletion in mild Parkinson's disease. Annals of Neurology, 1994, 35, 376-377.	2.8	12

#	ARTICLE	IF	CITATIONS
91	O-526, a piperidine analog of GBR 12909, retains high affinity for the dopamine transporter in monkey caudate-putamen. <i>European Journal of Pharmacology</i> , 1994, 267, 167-173.	2.7	19
92	The Discovery of an Unusually Selective and Novel Cocaine Analog: Difluoropine. Synthesis and Inhibition of Binding at Cocaine Recognition Sites. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 2001-2010.	2.9	88
93	[3H]CFT ([3H]win 35,428) accumulation in dopamine regions of monkey brain: comparison of a mature and an aged monkey. <i>Brain Research</i> , 1993, 611, 322-325.	1.1	20
94	A Primate Model of Huntington'S Disease: Functional Neural Transplantation and Ct-Guided Stereotactic Procedures. <i>Cell Transplantation</i> , 1992, 1, 313-322.	1.2	36
95	Distribution of cocaine recognition sites in monkey brain: II. Ex vivo autoradiography with [3H]CFT and [125I]RTI-55. <i>Synapse</i> , 1992, 12, 99-111.	0.6	55
96	Synthesis and receptor binding of N-substituted tropane derivatives. High-affinity ligands for the cocaine receptor. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 1728-1731.	2.9	50
97	Fluorescent probes for dopamine receptors: synthesis and characterization of fluorescein and 7-nitrobenz-2-oxa-1,3-diazol-4-yl conjugates of D-1 and D-2 receptor ligands. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 3235-3241.	2.9	39
98	Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. <i>Synapse</i> , 1991, 9, 43-49.	0.6	230
99	Distribution of cocaine recognition sites in monkey brain: I. In vitro autoradiography with [3H]CFT. <i>Synapse</i> , 1991, 9, 177-187.	0.6	65
100	Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35,428) in the monkey brain. <i>Synapse</i> , 1990, 6, 189-195.	0.6	93
101	D1 and D2 Dopamine Receptors in Caudate-Putamen of Nonhuman Primates ( <i>Macaca fascicularis</i> ). <i>Journal of Neurochemistry</i> , 1988, 51, 934-943.	2.1	67
102	Drug Potencies on Partially Purified Brain D2 Dopamine Receptors. <i>Journal of Neurochemistry</i> , 1985, 44, 856-861.	2.1	12
103	Solubilized receptors for [3H]dopamine (D3 binding sites) from canine brain. <i>Biochemical Pharmacology</i> , 1982, 31, 1183-1187.	2.0	11
104	Solubilized dopamine/neuroleptic receptors (D2-type). <i>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</i> , 1981, 5, 543-548.	0.6	7
105	Effects of Skim Milk, Whole Milk and Light Cream on Serum Tryptophan Binding and Brain Tryptophan Concentrations in Rats. <i>Journal of Nutrition</i> , 1975, 105, 1359-1362.	1.3	17
106	Relevance of free tryptophan in serum to tissue tryptophan concentrations. <i>Metabolism: Clinical and Experimental</i> , 1974, 23, 1107-1116.	1.5	155
107	Serum tryptophan level after carbohydrate ingestion: Selective decline in non-albumin-bound tryptophan coincident with reduction in serum free fatty acids. <i>Life Sciences</i> , 1973, 12, 57-64.	2.0	99
108	Formation of respiratory <sup>14</sup> CO <sub>2</sub> from variously labeled forms of tryptophan- <sup>14</sup> C in intact and adrenalectomized rats. <i>Archives of Biochemistry and Biophysics</i> , 1968, 125, 829-836.	1.4	41

#	ARTICLE	IF	CITATIONS
109	Effects of drugs on the metabolism of tryptophan.. Biochemical Pharmacology, 1968, 17, 1037-1047.	2.0	17
110	Metabolism of $\beta$ -methyltryptophan. Biochemical Pharmacology, 1965, 14, 1499-1506.	2.0	34